Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

AbstractContext Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance. At present, Shenqi Fuzheng injection (SFI) is widely accepted as an adjuvant therapy...

Full description

Bibliographic Details
Main Authors: Jiali Wang, Xianhai He, Zhirong Jia, Aiwen Yan, Kang Xiao, Shuo Liu, Mengjun Hou, Yaling Long, Xuansheng Ding
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Pharmaceutical Biology
Subjects:
Adjuvant therapy
EGFR-TKIs
drug resistance
cytokine pathway
Online Access:https://www.tandfonline.com/doi/10.1080/13880209.2023.2292266

Internet

https://www.tandfonline.com/doi/10.1080/13880209.2023.2292266

Similar Items